Artikel ; Online: Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Expert review of anti-infective therapy
2022 Band 20, Heft 8, Seite(n) 1135–1147
Abstract: Introduction: The development of long-acting (LA) drugs has changed the management of common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva (cabotegravir/Rilpivirine) is the first LA antiretroviral injectable drug ... ...
Abstract | Introduction: The development of long-acting (LA) drugs has changed the management of common medical conditions for human replication immunodeficiency virus (HIV). Cabenuva (cabotegravir/Rilpivirine) is the first LA antiretroviral injectable drug composed of nano-formulation of cabotegravir (CAB) and rilpivirine (RPV). Areas covered: In this review article, we aim to have a brief overview of results of major clinical trials that administrated Cabotegravir/Rilpivirine for patients considering the efficacy and safety profiles. Moreover, we discuss about CAB and RPV chemical structure, mechanism of action, activity against drug-sensitive and -resistant HIV, and pharmacodynamics/pharmacokinetics properties. Expert opinion: Based on the results of the ATLAS and FLAIR trials, Cabotegravir/Rilpivirine regimen once-monthly has shown equal effectivity to oral combination antiretroviral therapy (cART) in maintaining HIV-1 suppression in patients. Furthermore, ATLAS-2 M study revealed the non-inferiority of Cabotegravir/Rilpivirine regimen every 8 weeks compared to every 4 weeks. The injectable LA ART reduces the number of treatment intake as well as increases adherence, especially in patients with HIV-related stigma. Administration of extended-release agents probably minimize the risk of treatment-related toxicity and resistance related to sub-optimal adherence to oral ART, so Cabotegravir/Rilpivirine can be suggested as a suitable alternative for HIV infection control in current era. |
---|---|
Mesh-Begriff(e) | Anti-HIV Agents/adverse effects ; Anti-Retroviral Agents/therapeutic use ; Diketopiperazines ; Drug Combinations ; HIV Infections/drug therapy ; Humans ; Pharmaceutical Preparations ; Pyridones ; Rilpivirine/adverse effects |
Chemische Substanzen | Anti-HIV Agents ; Anti-Retroviral Agents ; Diketopiperazines ; Drug Combinations ; Pharmaceutical Preparations ; Pyridones ; cabotegravir, rilpivirine drug combination ; Rilpivirine (FI96A8X663) ; cabotegravir (HMH0132Z1Q) |
Sprache | Englisch |
Erscheinungsdatum | 2022-06-13 |
Erscheinungsland | England |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 2181279-2 |
ISSN | 1744-8336 ; 1478-7210 |
ISSN (online) | 1744-8336 |
ISSN | 1478-7210 |
DOI | 10.1080/14787210.2022.2081153 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 6106: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.